Evidence map›Paper›PMID 35529201›Full record

ArticleRSC advances2019

Catalyst-free hydrophosphination of alkenes in presence of 2-methyltetrahydrofuran: a green and easy access to a wide range of tertiary phosphines.

Damien Bissessar, Julien Egly, Thierry Achard, Pascal Steffanut, Stéphane Bellemin-Laponnaz

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Damien BissessarInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg, CNRS UMR 7504 23 Rue du Loess, BP 43 F-67034 Strasbourg Cedex 2 France bellemin@unistra.fr.
Julien EglyInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg, CNRS UMR 7504 23 Rue du Loess, BP 43 F-67034 Strasbourg Cedex 2 France bellemin@unistra.fr.
Thierry AchardInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg, CNRS UMR 7504 23 Rue du Loess, BP 43 F-67034 Strasbourg Cedex 2 France bellemin@unistra.fr.
Pascal SteffanutCLARIANT Plastics and Coatings AG Rothausstrasse 61 4132 Muttenz Switzerland.
Stéphane Bellemin-LaponnazInstitut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg, CNRS UMR 7504 23 Rue du Loess, BP 43 F-67034 Strasbourg Cedex 2 France bellemin@unistra.fr.ORCID https://orcid.org/0000-0001-9462-5703
Institut de Physique et Chimie des Matériaux de Strasbourg · FRClariant (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hydrophosphination reaction that is free of base, acid and catalyst, using only 2-methyltetrahydrofuran as additive has been performed. A new family of mono-, di-, tri- and tetra-phosphines compounds are obtained in good to excellent yields by adding diphenylphosphine to alkenes, mono- and polyfunctional acrylics (based on acrylate and methacrylate motifs) and acrylamide substrates. Addition of four equivalent of bio-mass derived 2-MeTHF into the reaction media improves both conversion and time of the reaction and reduces the sensitivity of the reactants over oxidation. This simple, straightforward and atom-economic method respects the principles of Green Chemistry. Furthermore, in each case this transformation shows an exclusive regioselectivity towards the anti-Markovnikov products.

Identifiers

PMID35529201
PMCPMC9070578
OpenAlexW2970580124

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.